



Completely filled IDS of 9-1-06

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) RESUBMISSION OF PTO Form 1449 September 1, 2006				Attorney Docket No. 056291-5241		Application No. 10/573,090	
				Applicants: HENNEQUIN et al.			
				Filing Date: March 15, 2006		Group Art Unit: 1624 Unassigned	
U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
TNT	1.	US 20020049197	April 25, 2002	Himmelsbach et al.	514	217.06	August 23, 2001
	2.	US 20020082270	June 27, 2002	Himmelsbach et al.	514	266.2	August 22, 2001
	3.	US 20020082271	June 27, 2002	Himmelsbach et al.	514	266.24	August 22, 2001
	4.	US 20020128553	September 12, 2002	Mishani et al.	600	431	March 12, 2001
	5.	US 20020169180	November 14, 2002	Himmelsbach et al.	514	266.4	December 10, 2001
	6.	US 20020173509	November 21, 2002	Himmelsbach et al.	514	234.5	December 17, 2001
	7.	US 20020177601	November 28, 2002	Himmelsbach et al.	514	266.2	August 23, 2001
	8.	US 20030149062	August 7, 2003	Jung et al.	514	266.22	January 29, 2003
	9.	US 20030158196	August 21, 2003	Jung et al.	514	234.2	February 7, 2003
	10.	US 20030225079	December 4, 2003	Singer et al.	514	233.8	May 8, 2003
	11.	US 20040044014	March 4, 2004	Himmelsbach et al.	514	266.4	April 17, 2003
	12.	US 20040048880	March 11, 2004	Himmelsbach et al.	514	266.2	March 27, 2003
	13.	US 20040176361	September 9, 2004	Fujio et al.	514	224.2	February 24, 2004
	14.	US 20050148607	July 7, 2005	Suzuki et al.	514	264.11	June 3, 2003
	15.	US 20050165035	July 28, 2005	Bradbury et al.	514	266.22	June 1, 2004
	16.	US 3,812,257	May 21, 1974	Yamamoto	514	266.21	April 7, 1972
	17.	US 3,971,783	July 27, 1976	Barnish et al.	514	284	April 26, 1974
	18.	US 4,335,127	June 15, 1982	Vandenberk et al.	514	266.22	October 12, 1979
	19.	US 4,921,863	May 1, 1990	Sugimoto et al.	514	319	February 17, 1988
	20.	US 5,411,963	May 2, 1995	Dreikorn et al.	514	266.3	July 19, 1993
	21.	US 5,457,105	October 10, 1995	Barker	514	234.5	August 2, 1994
	22.	US 5,616,582	April 1, 1997	Barker	514	234.5	June 15, 1995
	23.	US 5,747,498	May 5, 1998	Schnur et al.	514	266.4	May 28, 1996
	24.	US 5,770,599	June 23, 1998	Gibson	514	228.2	April 26, 1996
	25.	US 5,817,678	October 6, 1998	Kim et al.	514	326	November 15, 1996
	26.	US 6,127,366	October 3, 2000	Kim et al.	514	235.5	October 5, 1998
	27.	US 6,177,433	January 23, 2001	Uckun et al.	514	266.4	November 19, 1999
	28.	US 6,200,976	March 13, 2001	Ries et al.	514	249	March 29, 1999
	29.	US 6,297,258	October 2, 2001	Wissner et al.	514	313	August 1, 2000
	30.	US 6,313,127	November 6, 2001	Waterson et al.	514	253.01	July 31, 1998
	31.	US 6,541,491	April 1, 2003	Davies et al.	514	340	November 30, 2000
	32.	US 6,562,319	May 13, 2003	Mishani et al.	424	1.81	March 12, 2001
TNT	33.	US 6,617,329	September 9, 2003	Himmelsbach et al.	514	252.14	August 23, 2001
TNT	34.	US 6,653,305	November 25, 2003	Himmelsbach et al.	514	233.5	August 15, 2001
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner				Date Considered 7/9/09			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) RESUBMISSION OF PTO Form 1449 September 1, 2006				Attorney Docket No. 056291-5241		Application No. 10/573,090		
				Applicants: HENNEQUIN et al.				
				Filing Date: March 15, 2006		Group Art Unit: 1624 Unassigned		
U.S. PATENT DOCUMENTS								
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date		
TNT	35.	US 6,656,946	December 2, 2003	Himmelsbach et al.	514	266.4	August 22, 2001	
	36.	US 6,740,651	May 25, 2004	Himmelsbach et al.	514	228.8	August 22, 2001	
	37.	US 6,972,288	December 6, 2005	Himmelsbach et al.	514	234.8	February 6, 2002	
TNT								
FOREIGN PATENT DOCUMENTS								
Document No.	Date	Country	Applicant			Translation		
TNT	38.	DE 19908567	August 31, 2000	Germany	Boehringer Ingelheim Pharma KG			US 6,972,288
	39.	EP 0 288 563	May 11, 1994	EPO	Eisai Co., Ltd.			
	40.	EP 0 566 226	November 8, 1995	EPO	Zeneca Limited			
	41.	EP 0 585 371	April 17, 2002	EPO	Rhone-Poulenc Rorer Int.(Holdings) Inc.			
	42.	EP 0 669 324	August 30, 1995	EPO	Eisai Co., Ltd.			
	43.	EP 0 837 063	April 22, 1998	EPO	Pfizer Inc.			
	44.	EP 1 044 969	October 18, 2000	EPO	Pfizer Products Inc.			
	45.	EP 1 230 919	August 14, 2002	EPO	Warner-Lambert Company			
	46.	EP 1 369 418	December 10, 2003	EPO	Mitsubishi Pharma Corporation			
	47.	EP 1 548 008	June 29, 2005	EPO	Kirin Beer Kabushiki Kaisha			
	48.	GB 2,295,387	May 29, 1996	United Kingdom	Glaxo Inc.			
	49.	WO 88/02365	April 7, 1988	WIPO	EISAI Co., Ltd. Et al.			US 4,921,863
	50.	WO 92/20642	November 26, 1992	WIPO	Rhone-Poulenc Rorer Int.(Holdings) Inc.			
	51.	WO 95/00146	January 5, 1995	WIPO	Rhone-Poulenc Rorer Pharm. Inc.			
	52.	WO 95/15758	June 15, 1995	WIPO	Rhone-Poulenc Rorer Pharma. Inc.			
	53.	WO 96/09294	March 28, 1996	WIPO	The Wellcome Foundation Limited			
	54.	WO 96/30347	October 3, 1996	WIPO	Pfizer Inc.			
	55.	WO 96/33977	October 31, 1996	WIPO	Zeneca Limited			
	56.	WO 96/33978	October 31, 1996	WIPO	Zeneca Limited			
	57.	WO 96/33979	October 31, 1996	WIPO	Zeneca Limited			
	58.	WO 96/33980	October 31, 1996	WIPO	Zeneca Limited			
	59.	WO 96/33981	October 31, 1996	WIPO	Zeneca Limited			
	60.	WO 96/39145	December 12, 1996	WIPO	Rhone-Poulenc Rorer Pharma. Inc.			
	61.	WO 97/03069	January 30, 1997	WIPO	Glaxo Group Limited			
	62.	WO 97/06138	February 20, 1997	WIPO	Zeneca Limited			
	63.	WO 97/18813	May 29, 1997	WIPO	Merck & Co., Inc.			
	64.	WO 97/22596	June 26, 1997	WIPO	Zeneca Limited et al.			
	65.	WO 97/28128	August 7, 1997	WIPO	Zeneca Limited			
	66.	WO 97/30034	August 21, 1997	WIPO	Zeneca Limited			
	67.	WO 97/30035	August 21, 1997	WIPO	Zeneca Limited et al.			
TNT	68.	WO 97/30044	August 21, 1997	WIPO	Zeneca Limited			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
Examiner 				Date Considered 7/9/09				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) RESUBMISSION OF PTO Form 1449 September 1, 2006				Attorney Docket No. 056291-5241		Application No. 10/573,090	
				Applicants: HENNEQUIN et al.			
				Filing Date: March 15, 2006		Group Art Unit: 1624 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Applicant		Translation
TNT	69.	WO 97/32856	September 12, 1997	WIPO	Zeneca Limited et al.		
	70.	WO 97/38983	October 23, 1997	WIPO	Warner-Lambert Company		
	71.	WO 97/38994	October 23, 1997	WIPO	Zeneca Limited		
	72.	WO 98/02434	January 22, 1998	WIPO	Glaxo Group Limited		
	73.	WO 98/13354	April 2, 1998	WIPO	Zeneca Limited et al.		
	74.	WO 98/38984	September 11, 1998	WIPO	Sugen Inc.		
	75.	WO 99/06378	February 11, 1999	WIPO	Warner-Lambert Company		
	76.	WO 99/35132	July 15, 1999	WIPO	Glaxo Group Limited		
	77.	WO 99/54313	October 28, 1999	WIPO	Boehringer Ingelheim Pharma KG		US 6,200,976
	78.	WO 00/10981	March 2, 2000	WIPO	Parker Hughes Institute		
	79.	WO 00/12497	March 9, 2000	WIPO	Scios Inc.		
	80.	WO 00/18740	April 6, 2000	WIPO	American Cyanamid Company		
	81.	WO 00/20402	April 13, 2000	WIPO	Zeneca Limited		
	82.	WO 00/21955	April 20, 2000	WIPO	Zeneca Limited et al.		
	83.	WO 00/24718	May 4, 2000	WIPO	Akzo Nobel N.V.		
	84.	WO 00/31048	June 2, 2000	WIPO	Warner-Lambert Company		
	85.	WO 00/44728	August 3, 2000	WIPO	Pfizer Products Inc.		
	86.	WO 00/47212	August 17, 2000	WIPO	Zeneca-Pharma S.A.		
	87.	WO 00/51991	September 8, 2000	WIPO	Boehringer Ingelheim Pharma KG		
	88.	WO 00/55141	September 21, 2000	WIPO	Boehringer Ingelheim Pharma KG		
	89.	WO 00/56720	September 28, 2000	WIPO	Parker Hughes Institute		
	90.	WO 00/78735	December 28, 2000	WIPO	Boehringer Ingelheim Pharma KG		US 20020169180
	91.	WO 01/07432	February 1, 2001	WIPO	SmithKline Beecham PLC		
	92.	WO 01/19788	March 22, 2001	WIPO	Cor Therapeutics Inc.		
	93.	WO 01/21594	March 29, 2001	WIPO	AstraZeneca AB et al.		
	94.	WO 01/21595	March 29, 2001	WIPO	AstraZeneca AB et al.		
	95.	WO 01/21596	March 29, 2001	WIPO	AstraZeneca AB et al.		
	96.	WO 01/21597	March 29, 2001	WIPO	AstraZeneca AB et al.		
	97.	WO 01/32651	May 10, 2001	WIPO	AstraZeneca AB et al.		
	98.	WO 01/77085	October 18, 2001	WIPO	AstraZeneca AB et al.		
	99.	WO 01/94341	December 13, 2001	WIPO	AstraZeneca AB et al.		
	100.	WO 01/98277	December 27, 2001	WIPO	Pfizer Products Inc.		
TNT	101.	WO 02/16352	February 28, 2002	WIPO	AstraZeneca AB et al.		
TNT	102.	WO 02/18351	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG		US 20020082271
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner <i>W. Som</i>				Date Considered <i>7/9/09</i>			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) RESUBMISSION OF PTO Form 1449 September 1, 2006				Attorney Docket No. 056291-5241		Application No. 10/573,090	
				Applicants: HENNEQUIN et al			
				Filing Date: March 15, 2006		Group Art Unit: 1624 Unassigned	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Applicant	Translation	
TNT	103.	WO 02/18370	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG	US 20020082270	
	104.	WO 02/18372	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG	US 6,617,329	
	105.	WO 02/18373	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG	US 6,653,305	
	106.	WO 02/18376	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG	US 6,740,651	
	107.	WO 02/24684	March 28, 2002	WIPO	SmithKline Beecham PLC		
	108.	WO 02/30924	April 18, 2002	WIPO	AstraZeneca AB et al.		
	109.	WO 02/34744	May 2, 2002	WIPO	AstraZeneca AB et al.		
	110.	WO 02/41882	May 30, 2002	WIPO	Novartis AG et al.		
	111.	WO 02/44166	June 6, 2002	WIPO	AstraZeneca AB et al.		
	112.	WO 02/48117	June 20, 2002	WIPO	Fujisawa Pharmaceutical Co., Ltd.		
	113.	WO 02/50043	June 27, 2002	WIPO	Boehringer Ingelheim Pharma KG	US 20020173509	
	114.	WO 02/056882	July 25, 2002	WIPO	SmithKline Beecham PLC		
	115.	WO 02/066445	August 29, 2002	WIPO	Mitsubishi Pharma Corporation	EP 1 369 418	
	116.	WO 02/068409	September 6, 2002	WIPO	Merck & Co. Inc.		
	117.	WO 02/073235	September 19, 2002	WIPO	Yissum Research Development et al.		
	118.	WO 02/076976	October 3, 2002	WIPO	Bayer Corporation		
	119.	WO 02/092577	November 21, 2002	WIPO	AstraZeneca AB et al.		
	120.	WO 02/092578	November 21, 2002	WIPO	AstraZeneca AB et al.		
	121.	WO 02/097490	December 5, 2002	WIPO	LnI Technologies Canada Inc.		
	122.	WO 02/102315	December 27, 2002	WIPO	Bristol-Myers Squibb Company		
	123.	WO 03/000188	January 3, 2003	WIPO	Ariad Pharmaceuticals Inc.		
	124.	WO 03/031406	April 17, 2003	WIPO	IRM LLC		
	125.	WO 03/040108	May 15, 2003	WIPO	AstraZeneca AB et al.		
	126.	WO 03/040109	May 15, 2003	WIPO	AstraZeneca AB et al.		
	127.	WO 03/045364	June 5, 2003	WIPO	AstraZeneca AB et al.		
	128.	WO 03/045395	June 5, 2003	WIPO	AstraZeneca AB et al.		
	129.	WO 03/049740	June 19, 2003	WIPO	Pfizer Products Inc.		
	130.	WO 03/066060	August 14, 2003	WIPO	Boehringer Ingelheim Pharma GmbH...	US 20030149062	
	131.	WO 03/068264	August 21, 2003	WIPO	Boehringer Ingelheim Pharma GmbH...	US 20030158196	
	132.	WO 03/082290	October 9, 2003	WIPO	Boehringer Ingelheim Pharma GmbH...	US 20040048880	
	133.	WO 03/082831	October 9, 2003	WIPO	Boehringer Ingelheim Pharma GmbH...		
	134.	WO 03/089439	October 30, 2003	WIPO	Boehringer Ingelheim Pharma GmbH...	US 20040044014	
TNT	135.	WO 03/094921	November 20, 2003	WIPO	Boehringer Ingelheim Pharma GmbH...	US 20030225079	
TNT	136.	WO 03/099276	December 4, 2003	WIPO	Bristol-Myers Squibb Company		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner 				Date Considered 5/9/09			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Completely filled IDS of 9-1-06

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) RESUBMISSION OF PTO Form 1449 September 1, 2006		Attorney Docket No. 056291-5241	Application No. 10/573,090				
		Applicants: HENNEQUIN et al					
		Filing Date: March 15, 2006	Group Art Unit: Unassigned				
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Applicant	Translation	
TNT	137.	WO 03/101491	December 11, 2003	WIPO	Mitsubishi Pharma Corporation	US 20050148607	
	138.	WO 2004/006846	January 22, 2004	WIPO	Exelixis Inc.		
	139.	WO 2004/064718	August 5, 2004	WIPO	T.K. Signal Ltd.		
	140.	WO 2004/096226	November 11, 2004	WIPO	AstraZeneca AB et al.		
	141.	WO 2005/013998	February 17, 2005	WIPO	AstraZeneca AB et al.		
	142.	WO 2005/026156	March 24, 2005	WIPO	AstraZeneca AB et al.		
	143.	WO 2005/026157	March 24, 2005	WIPO	AstraZeneca AB et al.		
	144.	WO 2005/030757	April 7, 2005	WIPO	AstraZeneca AB et al.		
	145.	WO 2005/030765	April 7, 2005	WIPO	AstraZeneca AB et al.		
TNT	146.	WO 2005/075439	August 18, 2005	WIPO	AstraZeneca AB et al.		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
TNT	147.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR tyrosine Kinase Inhibitors: 6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003) .					
	148.	Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999) .					
	149.	Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains : Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300-1312 (2002) .					
	150.	Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrimido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000) .					
	151.	Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002) .					
	152.	Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997) .					
	153.	Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998) .					
	154.	Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001) .					
TNT	155.	Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .					
Examiner		Date Considered					
		7/9/09					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							